東ソー held a completion ceremony for its manufacturing facility for separation and purification agents used in biopharmaceuticals in Yokkaichi, Mie Prefecture. The investment amounted to approximately ¥14 billion, commercial operations are scheduled to begin in June 2027, and production capacity is expected to increase by approximately 20% from the current level.
東ソー completed a new facility for separation and purification agents used in biopharmaceutical manufacturing at its plant in Yokkaichi, Mie Prefecture, and held a completion ceremony. Total investment amounted to approximately ¥14 billion, and commercial operations are scheduled to begin in June 2027. The new facility is expected to increase production capacity by approximately 20% from the current level.
At the completion ceremony, President Mamoru Kuwata (桑田守) spoke of strengthening business continuity planning (BCP), building a stable supply system, and diversifying and developing advanced operations at the Yokkaichi Plant, while also expressing an intention to install a new plant.
Biopharmaceuticals are medicines whose active ingredients are proteins produced using genetic recombination or cell culture technology. They are considered to have high demand in areas including autoimmune diseases, cancer and rare diseases.
The completion of the facility is intended to strengthen the company's manufacturing structure and improve supply stability, and is positioned as part of its future business development.